The DOI matches its Crossref record.
A randomized dose-response trial of citicoline in acute ischemic stroke patients
Abstract
Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non-US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. There were no drug-related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.181486 · Cited by 2,475
Adams, H. P., Adams, R. J., Brott, T., del Zoppo, G. J., Furlan, A., Goldstein, L. B., Grubb, R. L., Higashida, R., Kidwell, C., Kwiatkowski, T. G., et al. (2003) · Stroke · doi:10.1161/01.str.0000064841.47697.22 · Cited by 1,245
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181486 · Cited by 904
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Metadata
- Authors
- Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., Sabounjian, L. A., & the Citicoline Stroke Study Group
- Venue
- Neurology
- Published
- 1997-09
- Volume
- 49
- Issue
- 3
- Pages
- 671-678
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1974964904
- Cited by
- 221
- References
- 0
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized dose-response trial of citicoline in acute ischemic stroke patients. https://app.cochat.ai/papers/10.1212/wnl.49.3.671
- The paper
- Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., Sabounjian, L. A., & the Citicoline Stroke Study Group. (1997). A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. https://doi.org/10.1212/wnl.49.3.671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.